Literature DB >> 3260161

OKT4+ T cell abnormality in patients with active systemic lupus erythematosus: HLA-DR antigen expressions.

S Raziuddin1, H B Danial, M Kelley.   

Abstract

The objective of this study was to define immunologic T cell abnormality characteristic of active systemic lupus erythematosus (SLE). Eight of nine patients who had severe clinical and laboratory manifestations of active SLE had a characteristically marked increase in OKT4+ and a decrease in OKT8+ T cells. Using OKIa1 and OKDR monoclonal antibody, we found that, in circulating blood of all patients with active SLE, an increased percentage of Ia+ and DR+ T cells is present compared to inactive SLE. Five of these active SLE patients had Tac+ antigens, an interleukin 2 receptor on OKT4+ and OKT8+ T cell subsets in resting blood. The present study demonstrates that Ia+ and DR+ antigens are selectively expressed on the majority of OKT4+ T cell subsets of all patients with active SLE, whereas Ia+ and DR+ antigens are expressed almost equally on both OKT4+ and OKT8+ T cell subsets in inactive SLE. The elevated percentage of Ia+, DR+, OKT4+ T cells in active SLE was accompanied by a highly depressed proliferative response to T cell mitogens, phytohemagglutinin and concanavalin A. However, OKT8+ T cell subsets in active SLE possessed a normal proliferative response to these T cell mitogens. We conclude that this abnormality of activated OKT4+ T cells bearing HLA-DR antigens may play a role in the development of active SLE.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3260161     DOI: 10.1016/0090-1229(88)90155-9

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  9 in total

1.  Immunoregulatory CD4+ CD45R+ suppressor/inducer T lymphocyte subsets and impaired cell-mediated immunity in patients with Down's syndrome.

Authors:  S Raziuddin; M E Elawad
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

2.  T lymphocyte activation in systemic lupus erythematosus analysed by proliferative response to nucleoplasmic proteins on nitrocellulose immunoblots.

Authors:  B N Pham; L Prin; D Gosset; P Y Hatron; B Devulder; A Capron; J P Dessaint
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

Review 3.  The role of cytokines in the immunopathogenesis of lupus.

Authors:  B S Handwerger; V Rus; L da Silva; C S Via
Journal:  Springer Semin Immunopathol       Date:  1994

4.  HLA-DR expression on lymphocyte subsets as a marker of disease activity in patients with systemic lupus erythematosus.

Authors:  J F Viallard; C Bloch-Michel; M Neau-Cransac; J L Taupin; S Garrigue; V Miossec; P Mercie; J L Pellegrin; J F Moreau
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

5.  Decreased production of immunoglobulin M and A in autoimmune pancreatitis.

Authors:  Masashi Taguchi; Yasuyuki Kihara; Yoshikuni Nagashio; Mitsuyoshi Yamamoto; Makoto Otsuki; Masaru Harada
Journal:  J Gastroenterol       Date:  2009-07-22       Impact factor: 7.527

6.  [The change of T lymphocyte subpopulations, interleukin-2 receptor and HLA-DR antigen in lupus nephritis patients].

Authors:  L Yu; J Z Tang; J L Zhang
Journal:  J Tongji Med Univ       Date:  1993

7.  Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases.

Authors:  M al-Janadi; S al-Balla; A al-Dalaan; S Raziuddin
Journal:  J Clin Immunol       Date:  1993-01       Impact factor: 8.317

8.  The apoptosis-1/Fas protein in human systemic lupus erythematosus.

Authors:  E Mysler; P Bini; J Drappa; P Ramos; S M Friedman; P H Krammer; K B Elkon
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

9.  Systemic lupus erythematosus of childhood onset: correlation between T cells expressing early and late activation antigens and disease activity.

Authors:  T Hara; S Hisano; Y Mizuno; K Hatae; M Kurokawa; K Ueda; T Sakaguchi; M Umene; M Mizukoshi
Journal:  Eur J Pediatr       Date:  1989-06       Impact factor: 3.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.